Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Tidal Investments LLC

Tidal Investments LLC boosted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 14.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,905 shares of the specialty pharmaceutical company's stock after purchasing an additional 3,028 shares during the quarter. Tidal Investments LLC's holdings in Jazz Pharmaceuticals were worth $2,944,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of JAZZ. Barclays PLC boosted its position in Jazz Pharmaceuticals by 19.1% in the 3rd quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company's stock worth $4,369,000 after purchasing an additional 6,289 shares in the last quarter. Park Avenue Securities LLC lifted its holdings in Jazz Pharmaceuticals by 19.5% in the 4th quarter. Park Avenue Securities LLC now owns 2,521 shares of the specialty pharmaceutical company's stock valued at $310,000 after purchasing an additional 412 shares in the last quarter. UMB Bank n.a. lifted its holdings in Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock valued at $38,000 after purchasing an additional 129 shares in the last quarter. Exchange Traded Concepts LLC lifted its holdings in Jazz Pharmaceuticals by 2.2% in the 4th quarter. Exchange Traded Concepts LLC now owns 7,045 shares of the specialty pharmaceutical company's stock valued at $868,000 after purchasing an additional 155 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in Jazz Pharmaceuticals by 83.7% in the 4th quarter. Blue Trust Inc. now owns 1,868 shares of the specialty pharmaceutical company's stock valued at $230,000 after purchasing an additional 851 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Analyst Ratings Changes

JAZZ has been the subject of a number of recent research reports. HC Wainwright raised their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. Truist Financial raised their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and raised their target price for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Finally, JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $182.79.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the company's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $116.35, for a total value of $116,350.00. Following the sale, the chief executive officer now directly owns 439,307 shares in the company, valued at $51,113,369.45. This represents a 0.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Neena M. Patil sold 3,800 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the sale, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. This represents a 10.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,236 shares of company stock worth $3,956,190 over the last three months. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

JAZZ traded up $0.92 during trading on Tuesday, reaching $108.99. 269,975 shares of the stock were exchanged, compared to its average volume of 1,082,521. The business's 50 day moving average price is $112.19 and its two-hundred day moving average price is $121.87. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company has a market capitalization of $6.72 billion, a price-to-earnings ratio of 15.35, a P/E/G ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals plc has a 1 year low of $95.49 and a 1 year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The firm's revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.68 earnings per share. As a group, equities research analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.